OrbiMed Launches New VC Fund with $950m

By Bio-IT World Staff

December 21, 2015 | OrbiMed, a leading investment firm focused on the healthcare sector, today announced the closing of its next venture capital fund, OrbiMed Private Investments VI, LP, with $950 million in limited partner commitments.

Investors in the Fund include some of the preeminent medical research institutions globally, along with leading endowments, foundations and sovereign wealth funds. Consistent with its predecessor Funds, the new Fund will invest in all stages and sectors of the healthcare industry, with a focus on biopharmaceuticals, medical devices, diagnostics and healthcare IT companies located in North America and Europe.

The new Fund is expected to invest in approximately 30 portfolio companies in amounts generally ranging from $10 million to $75 million.

Carl Gordon, a Partner at OrbiMed and Co-Head of Global Private Equity, noted in a press release, “The increasing pace of translation of science to medicine creates exciting opportunities for the Fund in areas such as oncology, central nervous system disease, and gene editing.”

“With this Fund we plan to accelerate our collaborations with leading life sciences entrepreneurs, strategic companies, research institutions and physicians, to drive the creation of novel therapies that address unmet medical needs,” commented Jonathan Silverstein in the same release, also an OrbiMed Partner and Co-Head of Global Private Equity.

OrbiMed’s current private fund investments include Good Start Genetics, Invitae, Natera, Practice Fusion, and many more.